HC Wainwright Reiterates “Buy” Rating for XOMA (NASDAQ:XOMA)

HC Wainwright restated their buy rating on shares of XOMA (NASDAQ:XOMA) in a report issued on Wednesday morning,Benzinga reports. They currently have a $104.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for XOMA’s Q1 2025 earnings at ($0.20) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.19) EPS, Q4 2025 earnings at $0.23 EPS, FY2025 earnings at ($0.29) EPS and FY2026 earnings at $0.12 EPS.

Separately, StockNews.com lowered XOMA from a “hold” rating to a “sell” rating in a research report on Tuesday, February 25th.

XOMA Stock Down 0.9 %

NASDAQ:XOMA opened at $20.88 on Wednesday. XOMA has a one year low of $19.92 and a one year high of $35.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 7.52 and a quick ratio of 7.52. The company has a market cap of $250.12 million, a PE ratio of -6.00 and a beta of 1.00. The firm’s 50 day simple moving average is $24.37 and its 200 day simple moving average is $27.14.

XOMA (NASDAQ:XOMA) last issued its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.17). The business had revenue of $8.70 million for the quarter, compared to analyst estimates of $8.75 million. XOMA had a negative return on equity of 24.95% and a negative net margin of 151.34%. On average, research analysts anticipate that XOMA will post -1.41 earnings per share for the current year.

Insider Transactions at XOMA

In other news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total transaction of $13,069,366.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

A number of large investors have recently bought and sold shares of the business. Nuveen Asset Management LLC grew its stake in XOMA by 3.8% during the fourth quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 527 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of XOMA by 95.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after buying an additional 795 shares in the last quarter. New York State Common Retirement Fund grew its position in shares of XOMA by 51.2% during the 4th quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after buying an additional 800 shares during the period. Eversept Partners LP increased its stake in shares of XOMA by 1.2% in the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after acquiring an additional 1,128 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of XOMA by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock valued at $4,840,000 after acquiring an additional 1,138 shares during the period. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.